CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This study is testing a new treatment called CB-011 for a type of cancer called multiple myeloma. The treatment is a type of therapy that uses specialized cells to target the cancer cells. The study is trying to find out the safest dose of the treatment and see if it works well for people whose cancer has come back or is not responding to other treatments.
This study is testing a new treatment called CB-011 for a type of cancer called multiple myeloma. The treatment is a type of therapy that uses specialized cells to target the cancer cells. The study is trying to find out the safest dose of the treatment and see if it works well for people whose cancer has come back or is not responding to other treatments.
Third Opinion AI Generated Synopsis
Trial Summary
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
